Mantle Cell Lymphoma | Tumor

CURE’s mantle cell lymphoma (MCL) page features the latest cancer news and updates on mantle cell lymphoma Through articles, videos, podcasts, and more, CURE brings readers the insights of experts, cancer survivors, patients, and advocates to ensure everyone is up to date in mantle cell lymphoma.

When MCL Relapses Early, Consider Different Treatment Options

July 13th 2021, 11:00pm


Patients with mantle cell lymphoma whose disease relapses within a year and a half of transplant tend to have worse outcomes and may want to consider new treatment regimens.

FDA Fast Tracks Drug to Treat MCL

July 2nd 2021, 9:00pm


The Food and Drug Administration granted a breakthrough therapy designation to a new drug that can be used to treat patients with mantle cell lymphoma.

MCL Treatment: Differences Exist Between Trial-Based Recommendations and Real-World Care

June 29th 2021, 9:00pm


Research found discrepancies between treatment recommended by clinical trial results and treatment that is typically given to patients with mantle cell lymphoma.

Treatment Intensity After Deferring Initial Therapy May Not Indicate Improved Survival in Mantle Cell Lymphoma

May 28th 2021, 1:00pm


Researchers observed no difference in overall and progression-free survival in patients with mantle cell lymphoma who started high-intensity treatment at least 90 days after receiving a diagnosis compared with a non-intensive therapy approach.

Tecartus May Contribute to Long-Term Responses in Relapsed/Refractory Mantle Cell Lymphoma

May 5th 2021, 1:00pm


Factors including progression-free survival, duration of response and overall survival were promising at 15 months in patients with relapsed/refractory mantle cell lymphoma.

Keep Inspiring

April 28th 2021, 12:30pm


Don’t let your disease define you

Your Previously Treated Mantle Cell Lymphoma (MCL)

April 28th 2021, 12:15pm


Navigating life with blood cancer

First-Line Immunochemotherapy With Maintenance Therapy May Lead to Long-Term Remission in Mantle Cell Lymphoma

April 9th 2021, 9:00pm


A high intensity immunochemotherapy with maintenance therapy led to 93.2% of patients achieving a complete response and 55.6% of patients with progression-free survival at five years.

Stem Cell Transplantation May Be Offered Less Often as a Treatment Option for Some Patients with Mantle Cell Lymphoma

April 8th 2021, 9:00pm


Researchers found that patients who were never married, had lower educational levels or had comorbidities were less likely to be suggested an autologous hematopoietic cell transplantation, which may underline a need for more informed decision making.

Patients With Previously Treated Multiple B-Cell Malignancies Respond Safely to Next-Generation BTK Inhibitor

April 6th 2021, 1:00pm


Pirtobrutinib was safe and effective in treating patients with chronic lymphocytic leukemia, small lymphocytic lymphoma, mantle cell lymphoma and Waldenstrom macroglobulinemia, some of whom developed intolerance or resistance to previous covalent BTK inhibitors.